To determine whether inhibition of WEE1 sensitizes ALL cell lines to clinically relevant chemotherapeutics, we first treated Jurkat cells with a panel of clinically relevant anti-leukemia agents with a range of doses to estimate the dose that inhibited proliferation by 50% (IC50;Supplementary Figure S1A, S1B). The gene discussed is WEE1; the disease is acute lymphoblastic leukemia.